Read evidence for local and systemic combinations
A combination can be biologically plausible and still fail to improve outcomes in a clinical trial.
Before you start: Prognostic and predictive evidence separates association from treatment selection. The injury lesson explains the priming hypothesis.
Why combine treatments?
A local intervention can reduce tumor burden and release material. Systemic therapy may treat disease elsewhere. Checkpoint inhibition can support some existing T-cell responses. These are distinct contributions, and their overlap does not establish synergy. Synergy requires a defined comparison demonstrating more than an expected combined effect; clinical benefit requires an appropriate patient outcome.
The order could affect inflammation, immune-cell availability and toxicity. That motivates experiments comparing sequences. It does not justify a universal rule that every patient must receive a checkpoint drug before and after ablation.
Match the study to the claim
| Study | Actual intervention and population | What it cannot establish |
|---|---|---|
| BOOSTER | Randomized ablation plus checkpoint inhibition versus checkpoint inhibition alone in advanced NSCLC | SBRT (stereotactic body radiation therapy) efficacy, TNBC benefit or a universal immune-priming schedule |
| PACIFIC | Randomized durvalumab after conventional chemoradiotherapy in unresectable stage III NSCLC without progression | That SBRT is required for checkpoint combinations, or that the regimen transfers to breast cancer |
| CURB | Randomized SBRT added to standard systemic care in oligoprogressive NSCLC or breast cancer | A demonstrated benefit in its breast cohort; pooled positivity does not erase subgroup differences |
| NRG-BR002 | Randomized metastasis-directed treatment in a studied oligometastatic breast-cancer population | Routine survival benefit from treating every limited breast recurrence locally |
A negative study narrows a claim; it does not prove that every local intervention is useless. Population, goal, endpoint and study size determine the conclusion. Symptom relief and local control can remain legitimate goals when a survival benefit is unproven.
Local control is not an abscopal endpoint
A treated lesion shrinking shows response at that site. An untreated lesion shrinking during systemic therapy has several possible explanations. An immune-cell percentage rising in a biopsy could reflect tumor loss, sampling location, inflammation or real recruitment. These are different claims requiring different controls.
Sid’s radioligand course occurred after dostarlimab and ipilimumab had begun in July 2024. The earlier teaching argument that RLT (radioligand therapy) alone produced his immune changes was based on an incorrect “no ICI yet” timeline. His story can suggest questions but cannot isolate the contribution of RLT, checkpoint drugs, sampling or other treatment.
Ask what randomization added
Randomization balances many measured and unmeasured differences on average. A single-arm series has no concurrent control for natural history, selection or concomitant care. Historical comparisons can differ in imaging frequency, treatment era and eligibility. A striking response is worth investigating, but its size does not replace a comparator.
Check whether a trial’s endpoint was local control, progression-free survival, overall survival or an exploratory immune marker. A hazard ratio and median survival describe different aspects of a curve. A mechanistic biomarker change does not itself prove that people live longer or better.
A worked reading exercise
An early study reports immune-cell recruitment after local treatment. A later randomized trial shows improved local control but no demonstrated overall survival benefit. The defensible account keeps both observations: an immune effect may occur, and the tested strategy has not established a survival benefit. Calling the procedure a “systemic vaccine” would skip that distinction.
Try it
A lung-cancer ablation trial is positive. Can a table label SBRT as the most evidence-supported immune-priming method for TNBC using that result?
Answer: No. It changes both the intervention and the cancer, neither of which the trial tested.
Explain it back: “Mechanism explains why to test a combination; the matched comparison explains what it actually improved.”
Explain it back
Preserve the population, intervention, comparator and endpoint when translating trial results.
Takeaway
Preserve the population, intervention, comparator and endpoint when translating trial results.
Next: Read a local-treatment proposal.
Sources and scope
General teaching, source-checked October 8, 2026. Expert and learner review remain pending. These lessons explain mechanisms and study interpretation; current choices are owned by the care plan and the local-priming question.